Efficacy and safety of erector spinae plane block for the treatment of osteoporotic vertebral compressive fractures.
Аннотация
OBJECTIVES
To evaluate the efficacy and safety of erector spinae plane block (ESPB) for the treatment of osteoporotic vertebral compressive fractures (OVCF).
METHODS
A total of 120 OVCF patients, admitted between March 2022 and September 2022, were enrolled and assigned to either a control group or a research group (n=60 each) in this retrospective study. The control group received conventional analgesic treatment, while the research group was treated with ESPB. Data were collected at three time points: before surgery (T0), after four treatment sessions (T1), and prior to discharge (T2). Pain intensity was assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ), which includes the Pain Rating Index (PRI), Visual Analogue Scale (VAS), and Present Pain Intensity (PPI). Inflammatory markers such as tumor necrosis factor-α (TNF-α), high-mobility group box-1 (HMGB-1), and high-sensitivity C-reactive protein (hs-CRP) were measured. Additional parameters included the number of intramuscular tramadol injections from days 4 to 7, sleep quality using the Pittsburgh Sleep Quality Index (PSQI), quality of life via the 16-item Assessment of Health-Related Quality of Life in Osteoporosis (ECOS-16), and treatment satisfaction.
RESULTS
The research group exhibited significant reductions in PRI, VAS, and PPI at T0, T1, and T2 compared to the control group (all P<0.05). At T1 and T2, pain scores in the research group were notably lower than those in the control group (all P<0.05). Two weeks post-treatment, levels of TNF-α, HMGB-1, and hs-CRP were significantly lower in the research group than in the control group and pre-treatment values (all P<0.05). Conversely, the ECOS-16 score was significantly higher in the research group (P<0.05). Furthermore, the research group required fewer intramuscular tramadol injections (days 4-7) and reported higher treatment satisfaction (both, P<0.05).
CONCLUSIONS
ESPB for OVCF patients demonstrated significant analgesic benefits, reducing pain, serum inflammatory markers, tramadol injections during days 4-7, and improving sleep quality, quality of life, and treatment satisfaction.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.